Humoral and cell-mediated immune responses to plant-produced African horse sickness virus VP7 quasi-crystals

Fearon, Shelley H; Dennis, Susan J.; Hitzeroth, Inga I.; Rybicki, Edward P.; Meyers, Ann E.

doi:10.1016/j.virusres.2020.198284

Cited by 3 publications

(1 citation statement)

References 73 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Expansion of CD8+ T cells has been observed in BTV- and AHSV-infected and vaccinated hosts [ 121 , 122 ]. Indeed, infected animals can mount CD8+ T-cell-mediated protective responses against homologous and heterologous non-related serotypes of BTV and AHSV—with highly conserved proteins VP7, NS1 and NS2 as potential targets—in the absence of neutralizing antibodies (Nabs) [ 123 , 124 , 125 , 126 , 127 , 128 , 129 , 130 , 131 ]. In this regard, DC cross-priming of cytotoxic T cells plays a critical role after VLP vaccination [ 132 ].…”

Section: Interaction Of Nano- or Microcarriers With The Immune Systemmentioning

confidence: 99%

Nanoparticle- and Microparticle-Based Vaccines against Orbiviruses of Veterinary Importance

et al. 2022

View full text Add to dashboard Cite

Bluetongue virus (BTV) and African horse sickness virus (AHSV) are widespread arboviruses that cause important economic losses in the livestock and equine industries, respectively. In addition to these, another arthropod-transmitted orbivirus known as epizootic hemorrhagic disease virus (EHDV) entails a major threat as there is a conducive landscape that nurtures its emergence in non-endemic countries. To date, only vaccinations with live attenuated or inactivated vaccines permit the control of these three viral diseases, although important drawbacks, e.g., low safety profile and effectiveness, and lack of DIVA (differentiation of infected from vaccinated animals) properties, constrain their usage as prophylactic measures. Moreover, a substantial number of serotypes of BTV, AHSV and EHDV have been described, with poor induction of cross-protective immune responses among serotypes. In the context of next-generation vaccine development, antigen delivery systems based on nano- or microparticles have gathered significant attention during the last few decades. A diversity of technologies, such as virus-like particles or self-assembled protein complexes, have been implemented for vaccine design against these viruses. In this work, we offer a comprehensive review of the nano- and microparticulated vaccine candidates against these three relevant orbiviruses. Additionally, we also review an innovative technology for antigen delivery based on the avian reovirus nonstructural protein muNS and we explore the prospective functionality of the nonstructural protein NS1 nanotubules as a BTV-based delivery platform.

show abstract

Section: Interaction Of Nano- or Microcarriers With The Immune Systemmentioning

confidence: 99%

Nanoparticle- and Microparticle-Based Vaccines against Orbiviruses of Veterinary Importance

et al. 2022

View full text Add to dashboard Cite

show abstract

Green biotherapeutics: overcoming challenges in plant-based expression platforms

Jadhav,

Khare

2024

Plant Biotechnol Rep

View full text Add to dashboard Cite

Identification of three novel linear B-cell epitopes on VP7 of African horse sickness virus using monoclonal antibodies

Hu,

Xu,

Wang

et al. 2024

Veterinary Microbiology

View full text Add to dashboard Cite

Humoral and cell-mediated immune responses to plant-produced African horse sickness virus VP7 quasi-crystals

Cited by 3 publications

References 73 publications

Nanoparticle- and Microparticle-Based Vaccines against Orbiviruses of Veterinary Importance

Nanoparticle- and Microparticle-Based Vaccines against Orbiviruses of Veterinary Importance

Green biotherapeutics: overcoming challenges in plant-based expression platforms

Identification of three novel linear B-cell epitopes on VP7 of African horse sickness virus using monoclonal antibodies

Contact Info

Product

Resources

About